Coronavirus in HIV Evaluation of Outcomes in Resource Limited Settings

COHIVE is an observational cohort study nested within four parent open label randomised clinical trials of first- and second-line antiretroviral therapies (ADVANCE – NCT03122262; D²EFT – NCT03017872; DolPHIN2 – NCT03249181 and NAMSAL-ANRS12313 – NCT02777229). COHIVE objective is to study the occurrence and outcomes of COVID-19 in people living with HIV across a variety of clinical settings. Taken together, these pivotal trials provide an established population and encompass a range of HIV therapies, HIV populations, and geographic regions to capture the full spectrum of these global public health emergency as it pertains to people living with HIV.